Paraoxonase-1 activity, malondialdehyde and glutathione peroxidase in non-alcoholic fatty liver disease and the effect of atorvastatin

Arab Journal of Gastroenterology

Volumn 12, Issue 2, 2011, Pages 80-85

  Samy, Waleed ^a   Hassanian, Mohammed A ^a  

^a TANTA UNIVERSITY   (Egypt)

Author keywords

Antioxidant; Atorvastatin; Lipid peroxidation; Non alcoholic fatty liver diseases; Paroxonase 1 activity

Indexed keywords

ARYLDIALKYLPHOSPHATASE 1; ATORVASTATIN; GLUTATHIONE PEROXIDASE; LIPID; MALONALDEHYDE;

ADULT; ARTICLE; CONTROLLED STUDY; DIET RESTRICTION; DRUG EFFECT; DYSLIPIDEMIA; ECHOGRAPHY; ENZYME ACTIVITY; FEMALE; GLUCOSE BLOOD LEVEL; HUMAN; IMPAIRED GLUCOSE TOLERANCE; LIPID ANALYSIS; LIPID PEROXIDATION; LIVER FUNCTION TEST; MAJOR CLINICAL STUDY; MALE; NONALCOHOLIC FATTY LIVER; OBESITY; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; TREATMENT DURATION;

ADULT; ALANINE TRANSAMINASE; ANTICHOLESTEREMIC AGENTS; ARYLDIALKYLPHOSPHATASE; ASPARTATE AMINOTRANSFERASES; CHOLESTEROL; CROSS-SECTIONAL STUDIES; DISEASE PROGRESSION; FATTY LIVER; FEMALE; GLUTATHIONE PEROXIDASE; HEPATITIS; HEPTANOIC ACIDS; HUMANS; LIPID PEROXIDATION; LIPOPROTEINS, HDL; LIPOPROTEINS, LDL; MALE; MALONDIALDEHYDE; MIDDLE AGED; OBESITY; OXIDATIVE STRESS; PYRROLES; RISK FACTORS; TRIGLYCERIDES;

EID: 79959228507     PISSN: 16871979     EISSN: 20902387     Source Type: Journal    
DOI: 10.1016/j.ajg.2011.04.008     Document Type: Article

References (28)

1. Schreuder T.C.M.A., Verwer B.J., van Nieuwkerk C.M.J., et al. Nonalcoholic fatty liver disease: an overview of current insights in pathogenesis, diagnosis and treatment. World J Gastroenterol 2008, 14(16):2474-2486.
2. Alba L.M., Lindor K. Review article: non-alcoholic fatty liver disease. Aliment Pharmacol Ther 2003, 17(8):977-986.
3. McCullough A.J. Update on nonalcoholic fatty liver disease. J Clin Gastroenterol 2002, 34(3):255-262.
4. Takuma Y., Nouso K. Nonalcoholic steatohepatitis-associated hepatocellular carcinoma: our case series and literature review. World J Gastroenterol 2010, 16(12):1436-1441.
5. Chitturi S., Abeygunasekera S., Farrell G.C., et al. NASH and insulin resistance: insulin hypersecretion and specific association with the insulin resistance syndrome. Hepatology 2002, 35(2):373-379.
6. Angulo P. Nonalcoholic fatty liver disease. N Engl J Med 2002, 346(16):1221-1231.
7. Edmison J., McCullough A.J. Pathogenesis of non-alcoholic steatohepatitis: human data. Clin Liver Dis 2007, 11(1):75-104.
8. Sozmen E.Y., Sozmen B., Girgin F.K., et al. Antioxidant enzymes and paraoxonase show a co-activity in preserving low-density lipoprotein from oxidation. Clin Exp Med 2001, 1(4):195-199.
9. Ferre N., Camps J., Prats E., et al. Serum paraoxonase activity: a new additional test for the improved evaluation of chronic liver damage. Clin Chem 2002, 48(2):261-268.
10. Chen X., Scholl T.O., Leskiw M.J., et al. Association of glutathione peroxidase activity with insulin resistance and dietary fat intake during normal pregnancy. J Clin Endocrinol Metab 2003, 88(12):5963-5968.
11. Cortez Pinto H., Camilo M.E. Non-alcoholic fatty liver disease/non-alcoholic steatohepatitis (NAFLD/NASH): diagnosis and clinical course. Best Pract Res Clin Gastroenterol 2004, 18(6 Spec. Iss.):1089-1104.
12. Bonow R.O., Eckel R.H. Diet obesity and cardiovascular risk. N Engl J Med 2003, 348(21):2057-2058.
13. Açikel M., Sunay S., Koplay M., et al. Evaluation of ultrasonographic fatty liver and severity of coronary atherosclerosis and obesity in patients undergoing coronary angiography. Anadolu Kardiyol Derg 2009, 9(4):273-279.
14. Yang Y., Sharma R., Sharma A., et al. Lipid peroxidation and cell cycle signaling: 4-hydroxynonenal, a key molecule in stress mediated signaling. Acta Biochim Pol 2003, 50(2):319-336.
15. Popov T., Neikovska L. Metod opredeleniia peroksidznoi aktivnosti krovi [Method of determining the peroxidase activity of blood]. Gig Sanit 1971, 36(10):89-91.
16. Grundy S.M., Cleeman J.I., Daniels S.R., et al. Diagnosis and management of the metabolic syndrome: an American heart association/national heart lung and blood institute scientific statement. Circulation 2005, 112(17):2735-2752.
17. Loguercio C., De Girolamo V., de Sio I., et al. Non-alcoholic fatty liver disease in an area of Southern Italy: main clinical, histological and pathophysiological aspects. J Hepatol 2001, 35(5):568-574.
18. Starkel P., Sempoux C., Leclercq I., et al. Oxidative stress, KLF6 and transforming growth factor-beta up-regulation differentiate non-alcoholic steatohepatitis progressing to fibrosis from uncomplicated steatosis in rats. J Hepatol 2003, 39(4):538-546.
19. Pagano G., Pacini G., Musso G., et al. Nonalcoholic steatohepatitis, insulin resistance and metabolic syndrome: further evidence for an etiologic association. Hepatology 2002, 35(2):367-372.
20. Schiff E.R., Sorrell M.F., Maddrey W.C. Schiff's diseases of the liver 2007, Pa: Lippincott Williams & Wilkins, Philadelphia. 10th ed.
21. Portincasa P., Grattagliano I., Palmieri V.O., et al. The emerging problem of nonalcoholic steatohepatitis (NASH). Rom J Gastroenterol 2005, 14(1):43-51.
22. Koruk M., Taysi S., Savas M.C., et al. Oxidative stress and enzymatic antioxidant status in patients with nonalcoholic steatohepatitis. Ann Clin Lab Sci 2004, 34(1):57-62.
23. Morton G.J., Gelling R.W., Niswender K.D., et al. Leptin regulates insulin sensitivity via phosphatidylinositol-3-OH kinase signaling in mediobasal hypothalamic neurons. Cell Metab 2005, 2(6):411-420.
24. Durrington PN., Mackness B., Mackness MI. Paraoxonase and atherosclerosis. Arterioscler Thromb Vasc Biol 2001, 21(4):473-480.
25. Kilic SS., Aydin S., Kilic N., et al. Serum arylesterase and paraoxonase activity in patients with chronic hepatitis. World J Gastroenterol 2005, 11(46):7351-7354.
26. Prakash M., Shetty JK., Tripathy S., et al. Serum paraoxonase in alcohol abusers associated with alcoholic liver disease. Clin Chim Acta 2007, 378(1-2):232-234.
27. Uygun A., Kadayifci A., Yesilova Z., et al. Serum leptin levels in patients with nonalcoholic steatohepatitis. Am J Gastroenterol 2000, 95(12):3584-3589.
28. Hennige AM., Stefan N., Kapp K., et al. Leptin down-regulates insulin action through phosphorylation of serine-318 in insulin receptor substrate 1. FASEB J 2006, 20(8):1206-1208.